Ovarian Cell Hormone Predicts Onset of Menopause
|
By LabMedica International staff writers Posted on 06 Jul 2010 |
|
Levels of a hormone, produced by cells in the ovary, can be used to predict when a woman's menopause will begin.
A hormonal blood test can accurately predict at what age a woman's reproductive status will change. Different quantities of the hormone in the blood can be used to assess when the permanent cessation of ovarian function will occur.
Scientists at the Shahid Beheshti University of Medical Sciences (Tehran, Iran) have measured the anti-Mullerian Hormone (AMH) concentration in women enrolled in a study since 1998. AMH controls the development of follicles in the ovaries, from which oocytes (eggs) develop and it has been suggested that AMH could be used for measuring ovarian function. Blood samples were taken at three yearly intervals, and they also collected information on the women's socioeconomic background and reproductive histories.
The results from the study enabled the scientists to make a more realistic assessment of women's reproductive status many years before they reach menopause. For example, if a 20-year-old woman has a concentration of serum AMH of 2.8 ng/mL they estimate that she will become menopausal between 35 to 38 years old. The statistical model used to correlate AMH levels at different ages could predict if women were likely to have an early menopause (before the age of 45). They found that AMH levels of 4.1 ng/mL or less predicted early menopause in 20-year-olds, AMH levels of 3.3 ng/mL predicted it in 25-year-olds, and AMH levels of 2.4 ng/mL predicted it in 30-year-olds. In contrast, AMH levels of at least 4.5 ng/mL at the age of 20, 3.8 ngl/mL at 25 and 2.9 ng/mL at 30 all predicted an age at menopause of over 50 years old. The results of the study were presented at the annual meeting of European Society of Human Reproduction and Embryology held in June, 2010 in Rome, Italy.
The estimates of ages at menopause based on AMH levels are of sufficient validity to guide medical practitioners in their day-to-day practice, so that they can help women with their family planning.
Related Links:
European Society of Human Reproduction and Embryology
A hormonal blood test can accurately predict at what age a woman's reproductive status will change. Different quantities of the hormone in the blood can be used to assess when the permanent cessation of ovarian function will occur.
Scientists at the Shahid Beheshti University of Medical Sciences (Tehran, Iran) have measured the anti-Mullerian Hormone (AMH) concentration in women enrolled in a study since 1998. AMH controls the development of follicles in the ovaries, from which oocytes (eggs) develop and it has been suggested that AMH could be used for measuring ovarian function. Blood samples were taken at three yearly intervals, and they also collected information on the women's socioeconomic background and reproductive histories.
The results from the study enabled the scientists to make a more realistic assessment of women's reproductive status many years before they reach menopause. For example, if a 20-year-old woman has a concentration of serum AMH of 2.8 ng/mL they estimate that she will become menopausal between 35 to 38 years old. The statistical model used to correlate AMH levels at different ages could predict if women were likely to have an early menopause (before the age of 45). They found that AMH levels of 4.1 ng/mL or less predicted early menopause in 20-year-olds, AMH levels of 3.3 ng/mL predicted it in 25-year-olds, and AMH levels of 2.4 ng/mL predicted it in 30-year-olds. In contrast, AMH levels of at least 4.5 ng/mL at the age of 20, 3.8 ngl/mL at 25 and 2.9 ng/mL at 30 all predicted an age at menopause of over 50 years old. The results of the study were presented at the annual meeting of European Society of Human Reproduction and Embryology held in June, 2010 in Rome, Italy.
The estimates of ages at menopause based on AMH levels are of sufficient validity to guide medical practitioners in their day-to-day practice, so that they can help women with their family planning.
Related Links:
European Society of Human Reproduction and Embryology
Gold Member
Hematology Analyzer
Medonic M32B
Gold Member
Hematology System
Medonic M16C
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
Pathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more
Technology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more